HomeCompareCSPHF vs PLD

CSPHF vs PLD: Dividend Comparison 2026

CSPHF yields 198.02% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSPHF wins by $106.19M in total portfolio value
10 years
CSPHF
CSPHF
● Live price
198.02%
Share price
$1.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.70M
Annual income
$56,534,499.65
Full CSPHF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — CSPHF vs PLD

📍 CSPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSPHFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSPHF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSPHF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSPHF
Annual income on $10K today (after 15% tax)
$16,831.68/yr
After 10yr DRIP, annual income (after tax)
$48,054,324.70/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, CSPHF beats the other by $43,586,353.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSPHF + PLD for your $10,000?

CSPHF: 50%PLD: 50%
100% PLD50/50100% CSPHF
Portfolio after 10yr
$59.60M
Annual income
$30,895,467.91/yr
Blended yield
51.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CSPHF
No analyst data
Altman Z
9.2
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSPHF buys
0
PLD buys
0
No recent congressional trades found for CSPHF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSPHFPLD
Forward yield198.02%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$112.70M$6.50M
Annual income after 10y$56,534,499.65$5,256,436.18
Total dividends collected$106.15M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CSPHF vs PLD ($10,000, DRIP)

YearCSPHF PortfolioCSPHF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$30,502$19,801.98$11,255$555.24+$19.2KCSPHF
2$89,086$56,448.56$13,062$1,018.59+$76.0KCSPHF
3$249,403$154,080.96$15,903$1,926.67+$233.5KCSPHF
4$670,003$403,142.26$20,839$3,823.32+$649.2KCSPHF
5$1,729,066$1,012,162.66$30,464$8,166.08+$1.70MCSPHF
6$4,291,289$2,441,188.37$52,054$19,457.30+$4.24MCSPHF
7$10,253,990$5,662,310.92$109,886$54,188.93+$10.14MCSPHF
8$23,616,660$12,644,890.45$304,030$186,451.18+$23.31MCSPHF
9$52,487,868$27,218,041.68$1,166,125$840,813.32+$51.32MCSPHF
10$112,696,518$56,534,499.65$6,504,190$5,256,436.18+$106.19MCSPHF

CSPHF vs PLD: Complete Analysis 2026

CSPHFStock

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.

Full CSPHF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CSPHF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSPHF vs SCHDCSPHF vs JEPICSPHF vs OCSPHF vs KOCSPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.